Symbiotec Pharmalab sets price band for Rs 1,757 crore IPO, to open on August 24
Symbiotec Pharmalab will launch its ₹1,757-crore IPO from August 24–27, 2026, with a price band of ₹938–988 per share. The minimum bid is 15 shares, requiring an investment of ₹14,820 at the upper price band. The IPO is expected to list on BSE and NSE on September 1, with allotment likely on August 28. At the upper band, the issue values the company at a steep 52 times FY26 diluted EPS.
Biopharmaceutical and biotechnology firm Symbiotec Pharmalab plans to issue shares worth Rs 1,757 crore through an initial public offering (IPO) on August 24, 2026. The company has set a price band ranging from Rs 938 to Rs 988 per share, with a minimum subscription requirement of 15 equity shares. The IPO is expected to list on both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on September 1, 2026, with final allotment anticipated on August 28 of the same year.
Symbiotec Pharmalab's valuation metrics, based on diluted earnings per share for fiscal 2026, indicate a price-to-earnings (P/E) ratio of 49.37 at the lower end of the band and rising to 52.00 at the upper end. The company's weighted average return on net worth over the past three years stands at 10.99%. With the IPO price band equating to 469 times the face value at the floor price and 494 times at the cap price, the offering is positioned as a premium investment in the pharmaceutical and biotechnology sectors.
The primary goal of the IPO proceeds is to bolster the company's financial standing by prepaying or refinancing certain outstanding loans and allocating the remaining funds towards general corporate purposes. Symbiotec Pharmalab, founded in 2002, is a prominent player in the biopharmaceutical and biotechnology domain, manufacturing active pharmaceutical ingredients, nutritional components, and specialized products for both domestic and international markets.
The company's manufacturing operations, which have achieved regulatory approvals from bodies such as the US FDA, EU-GMP authorities, and South Korea's Ministry of Food and Drug Safety, underscore its commitment to research-driven practices, quality control, and sustainability.
Written by urgent.news from The Economic Times - Top News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
